- Home
- ALLR
as 12-18-2024 9:46am EST
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 218.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -36.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $378.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Allarity Therapeutics Inc. News
ALLR Breaking Stock News: Dive into ALLR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
GlobeNewswire
a month ago
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
GlobeNewswire
2 months ago
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
GlobeNewswire
2 months ago
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
GlobeNewswire
3 months ago
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
GlobeNewswire
3 months ago
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
MT Newswires
3 months ago
Allarity Therapeutics Names Alexander Epshinsky CFO
GlobeNewswire
3 months ago
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare ALLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLR Allarity Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.